tiespectus (MK-8748) / Merck (MSD), INGENIA Therapeutics - LARVOL DELTA

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) (clinicaltrials.gov) - P3 | N=960 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetic Macular Edema • Diabetic Retinopathy • Macular Edema • Ophthalmology • Retinal Disorders

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=38 | Completed | Sponsor: EyeBiotech Ltd. | Active, not recruiting ➔ Completed

Trial completion • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005) (clinicaltrials.gov) - P3 | N=1104 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P3 trial • Diabetic Macular Edema • Diabetic Retinopathy • Macular Edema • Ophthalmology • Retinal Disorders

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) (clinicaltrials.gov) - P3 | N=960 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P3 trial • Diabetic Macular Edema • Diabetic Retinopathy • Macular Edema • Ophthalmology • Retinal Disorders

A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003) (clinicaltrialsregister.eu) - P2/3 | N=192 | Not yet recruiting | Sponsor: Eyebiotech Limited

New P2/3 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003) (clinicaltrialsregister.eu) - P2/3 | N=85 | Not yet recruiting | Sponsor: Eyebiotech Limited

New P2/3 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

MK-8748-002: A randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 in participants with neovascular age-related macular degeneration (NVAMD) (clinicaltrialsregister.eu) - P2/3 | N=20 | Not yet recruiting | Sponsor: Eyebiotech Limited

New P2/3 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) (clinicaltrials.gov) - P2/3 | N=960 | Recruiting | Sponsor: EyeBiotech Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) (clinicaltrials.gov) - P2/3 | N=960 | Recruiting | Sponsor: EyeBiotech Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) (clinicaltrials.gov) - P2/3 | N=960 | Not yet recruiting | Sponsor: EyeBiotech Ltd.

New P2/3 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration (Businesswire) - "The study, known as MALBEC, is the first trial of a broader late-phase development program for MK-8748, with a second study in NVAMD scheduled to begin this year (NCT07496567). The decision to advance into pivotal studies is based on results from the Phase 1/2a RIOJA trial..."

Trial status • Wet Age-related Macular Degeneration

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=38 | Active, not recruiting | Sponsor: EyeBiotech Ltd. | N=92 ➔ 38 | Recruiting ➔ Active, not recruiting

Enrollment change • Enrollment closed • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) (clinicaltrials.gov) - P2/3 | N=960 | Not yet recruiting | Sponsor: EyeBiotech Ltd.

New P2/3 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration